These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 3252557

  • 1. Hypothalamo-pituitary dopaminergic system in patients with myotonic dystrophy.
    Sakuma H, Takase S, Mizuno Y, Teramura K, Hanew K.
    Tohoku J Exp Med; 1988 Nov; 156(3):291-8. PubMed ID: 3252557
    [Abstract] [Full Text] [Related]

  • 2. Tuberoinfundibular dopaminergic system and anterior pituitary dopamine receptor in Shy-Drager syndrome.
    Konagaya Y, Konagaya M, Takayanagi T.
    J Neurol Sci; 1985 Jan; 67(1):93-103. PubMed ID: 3981215
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
    Hanew K, Sasaki A, Sato S, Goh M, Yoshinaga K.
    J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
    [Abstract] [Full Text] [Related]

  • 4. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M, Yamaji T.
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [Abstract] [Full Text] [Related]

  • 5. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA, Frohman LA.
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [Abstract] [Full Text] [Related]

  • 6. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F, Cesselin F, Bression D, Zygelman N, Brandi AM, Nousbaum A, Mauborgne A.
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [Abstract] [Full Text] [Related]

  • 7. Prolactin and growth hormone response to levodopa in affective illness.
    Linkowski P, Brauman H, Mendlewicz J.
    Neuropsychobiology; 1983 Nov; 9(2-3):108-12. PubMed ID: 6621850
    [Abstract] [Full Text] [Related]

  • 8. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients.
    Cusimano G, Capriani C, Bonifati V, Meco G.
    Acta Neurol Scand; 1991 Mar; 83(3):145-50. PubMed ID: 1903236
    [Abstract] [Full Text] [Related]

  • 9. Depending on the stimulus, central serotoninergic activation by fenfluramine blocks or does not alter growth hormone secretion in man.
    Casanueva FF, Villanueva L, Peñalva A, Cabezas-Cerrato J.
    Neuroendocrinology; 1984 Apr; 38(4):302-8. PubMed ID: 6374488
    [Abstract] [Full Text] [Related]

  • 10. L-dopa absorption and the pituitary-hypothalamic axis.
    Boyd AE, Angoff G, Long A, Mager M.
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1341-7. PubMed ID: 263355
    [Abstract] [Full Text] [Related]

  • 11. Stimulating action of sulpiride and pimozide on prolactin release. Effect on bromocriptine, L-dopa and metergoline administration.
    Delitala G.
    Acta Endocrinol (Copenh); 1977 Oct; 86(2):251-6. PubMed ID: 578618
    [Abstract] [Full Text] [Related]

  • 12. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A.
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [Abstract] [Full Text] [Related]

  • 13. Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man.
    Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO.
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1136-41. PubMed ID: 3553220
    [Abstract] [Full Text] [Related]

  • 14. Effect of some peptides on dopaminergic function in man.
    Lal S, Nair NP, Isaac I, Thavundayil J, Guyda H.
    J Neural Transm Suppl; 1990 Jun; 29():173-81. PubMed ID: 2113567
    [Abstract] [Full Text] [Related]

  • 15. Effect of sulpiride on serum growth hormone and prolactin concentrations following L-DOPA administration in man.
    Mori M, Kobayashi I, Shimoyama S, Uehara T, Nemoto T.
    Endocrinol Jpn; 1977 Apr; 24(2):149-53. PubMed ID: 406134
    [Abstract] [Full Text] [Related]

  • 16. Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine.
    Kamal TJ, Molitch ME.
    Am J Med Sci; 1992 Nov; 304(5):289-93. PubMed ID: 1332473
    [Abstract] [Full Text] [Related]

  • 17. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso RD, Rocco A.
    J Neural Transm; 1981 Nov; 51(1-2):123-34. PubMed ID: 7264625
    [Abstract] [Full Text] [Related]

  • 18. Dynamic evaluation of growth hormone (GH) and prolactin (hPRL) secretion in active acromegaly with high and low GH output.
    Tolis G, Kovacs L, Friesen H, Martin JB.
    Acta Endocrinol (Copenh); 1975 Feb; 78(2):251-7. PubMed ID: 803748
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.